Diurnal glucose paterns of exenatide once weekly: A 1-year study using continuous glucose monitoring with ambulatory glucose profile analysis

Endocrine Practice

Volumn 15, Issue 4, 2009, Pages 326-334

  Mazze, Roger ^a   Strock, Ellie ^a   Morgan, Blaine ^a   Wesley, David ^a   Bergenstal, Richard ^a   Cuddihy, Robert ^a  

^a INTERNATIONAL DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; MICROSPHERE; POLYMER; ANTIDIABETIC AGENT; PEPTIDE; VENOM;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; BODY WEIGHT; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSE REGIMEN; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT OUTCOME; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; MIDDLE AGED; PHYSIOLOGY;

BLOOD GLUCOSE; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PEPTIDES; VENOMS;

EID: 67649199832     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP09046.ORR     Document Type: Article

References (12)

1. Mazze RS, Strock E, Wesley D, et al. Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. Diabetes Technol Ther. 2008;10:149-159.
2. Ceriello A, Quagliaro L, Piconi L, et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes. 2004;53:701-710.
3. Ceriello A, Assaloni R, Da Ros R, et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation. 2005;111:2518-2524.
4. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295:1681-1687.
5. Drucker DJ, Nauck MA. The incretin system: glucagonlike peptide 1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705.
6. Drucker DJ, Buse JB, Taylor K, et al; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, openlabel, non-inferiority study. Lancet. 2008;372:1240-1250.
7. Fehse F, Trautmann M, Holst JJ, et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2005;90:5991-5997.
8. Ostenson CG. The pathophysiology of type 2 diabetes mellitus: an overview. Acta Physiolo Scand. 2001;171:241-247.
9. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ. 1990;300:230-235.
10. Mazze R. The future of self-monitored blood glucose: mean blood glucose versus glycosylated hemoglobin. Diabetes Technol Ther. 2008;10:93-101.
11. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.
12. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358:2560-2572.